GLP-1s and HS: The Metabolic Connection

Dr. Michael Payette discusses innovative approaches to treating hidradenitis suppurativa (HS), with special focus on how GLP-1s are revolutionizing treatment by targeting inflammation. The conversation explores comprehensive management strategies for this challenging inflammatory skin condition that has historically been difficult to treat effectively.

• Board-certified dermatologist Dr. Michael Payette specializes in hidradenitis suppurativa treatment
• HS is a challenging inflammatory skin condition often misdiagnosed for years
• GLP-1 inhibitors (like Ozempic, Wegovy) reduce inflammation by decreasing metabolically active fat cells that produce inflammatory cytokines
• Treatment approach includes four components: topical antibacterials, oral medications, injectable biologics, and GLP-1 inhibitors
• Insurance coverage for GLP-1s remains challenging but workarounds exist
• Mental health benefits include both direct improvement from disease control and potential anti-inflammatory effects in the brain
• Patient resources include HS Foundation website, online support groups, and specialized clinics
• Multiple new treatments are in clinical trials, offering hope for better options in the near future

If you're dealing with painful, recurring boils or nodules, especially in the armpits, groin, or under breasts, don't be afraid to ask your dermatologist about HS. Visit the HS Foundation website to find specialized providers in your area.